Bain Capital exits Emcure Pharma after selling remaining stake, ends 12-year bet

Bain Capital exits Emcure Pharma after selling remaining stake, ends 12-year bet


Investment firm Bain Capital on Thursday (June 25) exited pharmaceutical company Emcure Pharmaceuticals Ltd after selling its remaining stake of around 1%, marking the completion of its full exit and ending a 12-year investment in the company.

The equity firm had acquired a 13% stake in Emcure Pharmaceuticals from global investment firm Blackstone in December 2013.

The exit was completed in 2026 through two stake sale transactions by BC Investments IV. On June 9, 2026, the entity sold 36 lakh shares of Emcure Pharmaceuticals via a block deal at ₹1,700 per share, amounting to ₹612 crore.

ALSO READ | Emcure Pharma Q2 | Profit rises 25% to ₹243 crore, revenue up 13% YoY

Earlier, on April 30, 2026, Bain Capital divested nearly a 1% stake in the company through open market transactions. BC Investments IV sold 18 lakh shares, representing a 0.95% stake, for over ₹289 crore.

Fourth Quarter Results

Net profit for the quarter rose 29% year-on-year to ₹243 crore from ₹189 crore. Revenue increased 16.7% to ₹2,469.7 crore compared to ₹2,116.2 crore in the year-ago period, reflecting healthy traction across key markets. EBITDA grew 19.2% to ₹479.5 crore, while margins improved marginally to 19.4% from 19% a year earlier.

The company’s international business remained the key growth driver, with sales rising 25.7% YoY to ₹1,493 crore, supported by base business ramp-up and new product launches. Domestic sales came in at ₹977 crore, up 5.2% YoY, impacted by softer performance in the Zuventus portfolio and organisational restructuring.

ALSO READ | Emcure Pharma receives 7 US FDA observations for Sanand formulations facility in Gujarat

The board recommended a final dividend of ₹3.60 per share for FY26, subject to shareholder approval. It also approved the re-appointment of Dr Mukund Gurjar as Whole-time Director for one year from August 2026, and Satish Mehta as Managing Director for five years from April 2027.

Pune-based firm Emcure Pharmaceuticals is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Shares of Emcure Pharmaceuticals Ltd ended at ₹1,881.90, up by ₹43.75, or 2.38%, on the BSE.

ALSO READ | Emcure Pharma cuts Poviztra starting dose price by 55% to boost patient access



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *